Vaccines Candidates in Clinical Trials

About Trial Phases

Last Updated 15 October 2021.

51 Vaccines in Phase 3 Clinical Trials

• Nanogen
  Nanocovax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 1 country

  Protein Subunit

• FBRI
  EpiVacCorona

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 2 countries

  3 trials in 1 country

  Protein Subunit

• Instituto Finlay de Vacunas Cuba
  FINLAY-FR-1A

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 1 country

  Protein Subunit

• Anhui Zhifei Longcom
  ZF2001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 3 countries

  8 trials in 1 country

  Protein Subunit

• Novavax
  NVX-CoV2373

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  10 trials in 7 countries

  Protein Subunit

• Razi Vaccine and Serum Research Institute
  Razi Cov Pars

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 1 country

  Protein Subunit

• Sanofi/GSK
  Recombinant Protein

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  Protein Subunit

• Serum Institute of India
  COVOVAX

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  2 trials in 1 country

  Protein Subunit

• COVAXX
  UB-612

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  Protein Subunit

• Clover
  SCB-2019

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  7 trials in 2 countries

  Protein Subunit

• Sinocelltech
  SCTV01C

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 0 countries

  Protein Subunit

• Center for Genetic Engineering and Biotechnology (CIGB)
  CIGB-66

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 4 countries

  5 trials in 1 country

  Protein Subunit

• SK Bioscience Co Ltd
  GBP510

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  Protein Subunit

• Vaxine/CinnaGen Co.
  COVAX-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  4 trials in 2 countries

  Protein Subunit

• West China Hospital
  Recombinant (Sf9 cell)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 4 countries

  Protein Subunit

• Instituto Finlay de Vacunas Cuba
  FINLAY-FR-2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 1 country

  Protein Subunit

• Medicago
  Plant-based VLP

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  VLP

• AnGes
  AG0302-COVID19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  6 trials in 1 country

  DNA

• Zydus Cadila
  ZyCoV-D

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  5 trials in 1 country

  DNA

• Genexine
  GX-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  6 trials in 1 country

  DNA

• Inovio
  INO-4800

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  6 trials in 1 country

  DNA

• Arcturus Therapeutics Inc
  ARCT-154

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 3 countries

  RNA

• Walvax
  mRNA

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  RNA

• Moderna
  mRNA-1273

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 76 countries

  30 trials in 2 countries

  RNA

• Moderna
  mRNA-1273.211

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  2 trials in 1 country

  RNA

• Moderna
  mRNA-1273.617.2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162b1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 2 countries

  RNA

• Pfizer/BioNTech
  BNT162b2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 103 countries

  37 trials in 2 countries

  RNA

• Pfizer/BioNTech
  BNT162b2s01

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 1 country

  RNA

• CanSino
  Ad5-nCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 9 countries

  11 trials in 1 country

  Non Replicating Viral Vector

• Gamaleya
  Sputnik Light

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 18 countries

  4 trials in 2 countries

  Non Replicating Viral Vector

• Serum Institute of India
  Covishield (Oxford/AstraZeneca formulation)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 46 countries

  2 trials in 1 country

  Non Replicating Viral Vector

• Gamaleya
  Sputnik V

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 72 countries

  21 trials in 2 countries

  Non Replicating Viral Vector

• Janssen (Johnson & Johnson)
  Ad26.COV2.S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 75 countries

  13 trials in 2 countries

  Non Replicating Viral Vector

• ReiThera
  GRAd-COV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  AZD1222

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 124 countries

  45 trials in 2 countries

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  AZD2816

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  2 trials in 2 countries

  Non Replicating Viral Vector

• Israel Institute for Biological Research (IIBR)
  IIBR-100

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  Replicating Viral Vector

• Wantai
  DelNS1-2019-nCoV-RBD-OPT

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 2 countries

  Replicating Viral Vector

• Valneva
  VLA2001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 2 countries

  Inactivated

• Minhai Biotechnology Co
  SARS-CoV-2 Vaccine (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  5 trials in 1 country

  Inactivated

• Bharat Biotech
  Covaxin

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 9 countries

  7 trials in 1 country

  Inactivated

• Valneva
  VLA2101

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  1 trial in 1 country

  Inactivated

• Kazakhstan RIBSP
  QazVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 2 countries

  3 trials in 1 country

  Inactivated

• Health Institutes of Turkey
  ERUCOV-VAC

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  Inactivated

• Sinopharm (Wuhan)
  Inactivated (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 2 countries

  8 trials in 7 countries

  Inactivated

• Sinopharm (Beijing)
  BBIBP-CorV (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 66 countries

  14 trials in 2 countries

  Inactivated

• Chinese Academy of Medical Sciences
  Inactivated (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  6 trials in 2 countries

  Inactivated

• Shifa Pharmed Industrial Co
  COVID-19 Inactivated Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  4 trials in 1 country

  Inactivated

• Organization of Defensive Innovation and Research
  FAKHRAVAC (MIVAC)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 1 country

  Inactivated

• Sinovac
  CoronaVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 41 countries

  22 trials in 1 country

  Inactivated

57 Vaccines in Phase 2 Clinical Trials

• National Vaccine and Serum Institute
  Recombinant SARS-CoV-2 Vaccine (CHO Cell)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Medigen
  MVC-COV1901

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  7 trials in 1 country

  Protein Subunit

• Laboratorios Hipra SA
  COVID-19 vaccine HIPRA

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Tuebingen
  CoVac-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  3 trials in 1 country

  Protein Subunit

• Kentucky Bioprocessing
  KBP-201

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Instituto Finlay de Vacunas Cuba
  FINLAY-FR-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  3 trials in 1 country

  Protein Subunit

• University Medical Center Groningen
  AKS-452

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Icosavax
  IVX-411

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Novavax
  ICC Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Novavax
  SII B.1.351

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• EuBiologics Co Ltd
  EuCorVac-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Novavax
  SII B.1.617.2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Novavax
  SII Bivalent

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Clover
  SCB-2020S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 0 countries

  Protein Subunit

• University of Saskatchewan
  COVAC-2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Research Institute for Biological Safety Problems
  QazCoVac-P

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Shanghai Zerun Biotechnology, Walvax Biotechnology
  202-CoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Center for Genetic Engineering and Biotechnology (CIGB)
  CIGB-669

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Biological E Limited
  BECOV2D

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Biological E Limited
  BECOV2C

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  0 trials in 1 country

  Protein Subunit

• Biological E Limited
  BECOV2B

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Biological E Limited
  BECOV2A

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Shionogi
  S-268019

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Takeda
  TAK-019 (Novavax formulation)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Radboud University
  ABNCoV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 2 countries

  VLP

• The Scientific and Technological Research Council of Turkey
  SARS-CoV-2 VLP Vaccine Alpha Variant

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 1 country

  VLP

• The Scientific and Technological Research Council of Turkey
  SARS-CoV-2 VLP Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  VLP

• SpyBiotech
  RBD SARS-CoV-2 HBsAg VLP

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  VLP

• VBI Vaccines Inc
  VBI-2902a

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  VLP

• Takis
  COVID-eVax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• AnGes
  AG0301-COVID19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• Vaccibody AS
  VB10.2129

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• GeneOne Life Science Inc
  GLS-5310

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• Entos Pharmaceuticals Inc
  Covigenix VAX-001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• Vaccibody AS
  VB10.2210

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• Takeda
  TAK-919 (Moderna formulation)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  2 trials in 1 country

  RNA

• Arcturus Therapeutics Inc
  ARCT-165

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 2 countries

  RNA

• Arcturus Therapeutics Inc
  LUNAR-COV19/ARCT-021

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  6 trials in 2 countries

  RNA

• Chulalongkorn University
  ChulaCov19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Daiichi Sankyo Co Ltd
  DS-5670a

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Gennova Biopharmaceuticals Limited
  HGCO19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162c2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162b3

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162a1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Elixirgen Therapeutics Inc
  EXG-5003

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Vaxart
  VXA-CoV2-1.1-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Universitätsklinikum Hamburg-Eppendorf
  MVA-SARS-2-ST

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Non Replicating Viral Vector

• Mahidol University
  NDV-HXP-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  4 trials in 2 countries

  Non Replicating Viral Vector

• Shenzhen Geno-Immune Medical Institute
  LV-SMENP

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Non Replicating Viral Vector

• Institute of Vaccines and Medical Biologicals
  COVIVAC

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  4 trials in 2 countries

  Non Replicating Viral Vector

• ImmunityBio Inc
  hAd5-Covid-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  7 trials in 1 country

  Non Replicating Viral Vector

• Biocad
  BCD-250

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Non Replicating Viral Vector

• City of Hope Medical Center
  COH04S1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Replicating Viral Vector

• Cellid Co
  AdCLD-CoV19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Replicating Viral Vector

• Aivita Biomedical Inc
  AV-COVID-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  4 trials in 1 country

  Replicating Viral Vector

• KM Biologics Co Ltd
  KD-414

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Inactivated

• Chumakov Center
  KoviVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  2 trials in 1 country

  Inactivated

37 Vaccines in Phase 1 Clinical Trials

• Adimmune Corporation
  AdimrSC-2f

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• Jiangsu Rec-Biotechnology Co Ltd
  ReCOV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• US Army Medical Research and Development Command
  SpFN COVID-19 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• SK Bioscience Co Ltd
  NBP2001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• OSE Immunotherapeutics
  CoVepiT

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• Livzon Mabpharm Inc
  V-01

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  3 trials in 1 country

  Protein Subunit

• VaxForm
  CoV2-OGEN1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 0 countries

  Protein Subunit

• Baiya Phytopharm Co Ltd
  Baiya SARS-CoV-2 Vax 1 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 0 countries

  Protein Subunit

• Codagenix Inc
  COVI-VAC

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Live-Attenuated

• Bagheiat-allah University of Medical Sciences
  COVID-19 Recombinant RBD Protein Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• Scancell
  COVIDITY

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  DNA

• Providence Health & Services
  CORVax12

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  DNA

• University of Sydney
  COVIGEN

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  DNA

• Symvivo
  bacTRL-Spike

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  DNA

• MRC/UVRI and LSHTM Uganda Research Unit
  LNP-nCOV saRNA-02 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Stemirna Therapeutics Co Ltd
  mRNACOVID-19 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Providence Therapeutics Holdings Inc
  PTX-COVID19-B

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Moderna
  mRNA-1283

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• SENAI CIMATEC
  HDT-301

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 0 countries

  RNA

• GlaxoSmithKline
  CoV2 SAM (LNP)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Moderna
  mRNA-1273.351

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Tetherex Pharmaceuticals Corporation
  SC-Ad6-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Universitatsklinikum Hamburg-Eppendorf
  MVA-SARS-2-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Vaxart
  VXA-CoV2-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• CyanVac LLC
  CVXGA1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• EnGeneIC
  COVID-19-EDV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Bharat Biotech
  BBV154

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• NIAID
  SAM-LNP-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• AMMS
  Ad5-nCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Cellid Co
  AdCLD-CoV19-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• NIAID
  ChAdV68-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Shenzhen Geno-Immune Medical Institute
  Covid-19/aAPC

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• The University of Hong Kong
  DelNS1-nCoV-RBD LAIV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• Meissa Vaccines Inc
  MV-014-212

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• The Scientific and Technological Research Council of Turkey
  Adjuvanted Inactivated Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Inactivated

• Laboratorio Avi-Mex
  Recombinant NDV Vectored Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Inactivated

• Kocak Farma
  Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Inactivated

8 Vaccines are No Longer Progressing

• Curevac
  CVnCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  9 trials in 2 countries

  RNA

• Merck Sharp & Dohme Corp
  V591

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 3 countries

  Replicating Viral Vector

• Sanofi Pasteur
  MRT5500

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Altimmune Inc
  AdCOVID

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Imperial
  LNP-nCoVsaRNA

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Institut Pasteur
  COVID-19-101

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 2 countries

  Replicating Viral Vector

• Merck Sharp & Dohme Corp
  V590

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• Queensland
  Sclamp

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit